ArticleJACC. Asia2024
SCORE and SCORE2 in East Asian Population: A Performance Comparison.
Article in JACC. Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- SCORE2-Older Persons (SCORE2-OP): Validation and Added Value of Excessive Daytime Sleepiness in a French Cohort.Journal of the American Geriatrics Society · 2025Article
- Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea: Implications for East Asians?JACC. Asia · 2025Review
- Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model.European heart journal · 2025Article
- How do we stem the tide? Refocusing efforts for prevention of early onset atherosclerotic cardiovascular disease: we should look upstream.European journal of preventive cardiology · 2025Article
- Development and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older.BMC geriatrics · 2025Article
- Predicting Short-Term Risk of Cardiovascular Events in the Elderly Population: A Retrospective Study in Shanghai, China.Clinical interventions in aging · 2025Article
- Reassessing Cardiovascular Risk Stratification in Vietnam: Insights from SCORE2 and the Original SCORE Model.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025Article
- Agreement Between Cardiovascular Risk Assessment Models (SCORE2, Framingham, ASCVD-2013, and SCORE2-OP) in Adults Aged 70 Years or Older: A Population-Based Study.Clinical Medicine Insights. Cardiology · 2025Article
- Correlation and Agreement Between the SCORE2 and PREVENT 10-Year Atherosclerotic Cardiovascular Disease Risk Scores: Insights from Coronary Computed Tomography Angiography.Diagnostics (Basel, Switzerland) · 2024Article
- Cardiovascular Risk Prediction Model in Asians: Current Status and Future Direction.JACC. Asia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systematic COronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons (OP) models have been proposed as new cardiovascular risk evaluation tools. Objectives: This study evaluated the performance of SCORE/SCORE-OP and SCORE2/SCORE2-OP in the East Asian population by using population-based cohort data from the National Health Insurance Service (NHIS) Health Screening Cohort of Korea. Methods: A total of 324,384 NHIS examinees from 2004 to 2005 were divided into 5 age groups: 40-49 years, 50-59 years, 60-69 years,70-79 years, and more than 80 years. The examinees had their predicted cardiovascular disease risks calculated by using SCORE, SCORE2, SCORE-OP, and SCORE2-OP models. The low-risk model was applied on the basis of the cohort's observed event rates. The observed and predicted cardiovascular risks were compared. Results: A total of 324,384 subjects were included (mean age 51.4 ± 7.3 years; women, 37.9% for the SCORE/SCORE2 group and mean age 73.0 ± 2.8 years; women, 47.5% for the SCORE/SCORE2-OP group). Over a median follow-up of 9 years, cardiovascular events occurred in 15.0% and 28.9% in SCORE/SCORE2 and SCORE/SCORE2-OP groups, respectively. The SCORE/SCORE-OP model underestimated cardiovascular disease risk in young men (aged 40-49 years) and women (aged 40-59 years) and overestimated it in older age groups. In contrast, SCORE2/SCORE2-OP invariably overestimated the risk in all age groups and sexes. SCORE2/SCORE2-OP showed no improvement in Harrell's concordance index (C-index) compared with SCORE/SCORE-OP. Calibration plots favored SCORE2 over SCORE but not SCORE2-OP over SCORE-OP. Conclusions: Both SCORE2/SCORE2-OP and SCORE/SCORE-OP overestimated cardiovascular disease risk with low performance. SCORE2/SCORE2-OP showed slight improvement over older versions, but modifications are necessary for the East Asian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.